华婧 祝

• Provide safety insights to study proposal and study design of AZ China post-marketing studies, review CSP, ICF, CRF, CSR and other related documents for these studies, and present safety management and reporting requirements at investigator meetings • Prepare RCP, LRMP and other required safety related documents for CTA and NDA registration • Fully implement China local RMPs including aRMM to fulfill local regulations and global requirements • Lead Drug Intensive Monitoring (DIM) projects to fulfill China PV regulation • Collaborate with cross-functions to support product license renewal, China NRDL negotiation, Chinese PI revision, and health authority safety related query handling • Conduct local safety review for assigned products at product level and study level monthly • Engage in China PV audit and inspection

• Responsible for melanoma, renal cell carcinoma and TSC-AML (rare disease) products • Collect and report of consolidated KOL insights that may impact company development plans, trial designs, launch strategies and tactics • Support new brand launch readiness for dabrafenib and trametinib

• Formulate clear and feasible regional marketing strategies for critical care products, including patient monitor and ventilator • Collaborate with internal and external stakeholders to ensure cross-functional integration, coordination and alignment to enable effective and efficient execution of marketing strategies • Participates in competitive intelligence and market assessment activities

• Provide consultation to Chinese patients on overseas treatment and remote medical consultation • Refer Chinese cancer patients to global top-ranked hospitals to receive anti-cancer therapy not approved in China, including targeted therapy (e.g. AZD9291) and immunotherapy (e.g. Nivolumab + Ipilimumab) • Establish and operate Hangzhou Branch and formulate marketing strategies for overseas treatment

• Major: Anesthesiology • GPA top 10%; The First Prize Scholarship of Shanghai Jiao Tong University • Scientific research training at University of Western Australia and University of Basel • 1-year clinical training in Shanghai Renji Hospital and 3-year clinical training in Shanghai Xinhua Hospital